Spruce Biosciences
Update in progressSPRB (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Spruce Biosciences, Inc. is a biopharmaceutical company developing therapies for neurological and related disorders. Its programs include TA-ERT for Sanfilippo Syndrome Type B; Tildacerfont for congenital adrenal hyperplasia (CAH), including a Japan collaboration with Kaken Pharmaceutical to develop and commercialize it; and SPR202 for CAH. The company also has licensing and collaboration agreements with Eli Lilly. Founded in 2014, it is based in South San Francisco, California.
Company score
- Sentiment
- 0.19
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.17
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.13
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Javier Szwarcberg M.D., M.P.H.
- Founded2014
- Employees22
- Websitesprucebio.com
Identifiers
- ISINUS85209E1091
- FIGIBBG00HYZ1522
- CUSIP85209E109
- CIK0001683553